ViraQuest, Inc. is a biotechnology company specializing in the production of adenoviral vectors and retains the exclusive commercial rights to RAPAd® technology. Using the patented processes unique to RAPAd® (U.S. Patent #6,830,920) for the generation of new constructs, we can provide the fastest turn around time of any supplier in the industry. Utilizing the RAPAd® technology combined with easy subcloning steps results in production of your custom adenovirus constructs in as little as three weeks without complications of revertants. ViraQuest, Inc. is your partner in research. If you don't succeed, we don't succeed. We offer an array of adenovirus services to meet your needs including novel constructs, dual-expressing vectors, amplifications and isolations. We are committed to providing you with the best research materials and support in the adenovirus field. Let our vectors keep your research headed in the right direction.